LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

DexCom Inc

Închisă

SectorSănătate

69.73 1.19

Rezumat

Modificarea prețului

24h

Curent

Minim

68.85

Maxim

71.01

Indicatori cheie

By Trading Economics

Venit

-68M

200M

Vânzări

-68M

1.2B

P/E

Medie Sector

29.644

50.958

EPS

0.56

Marjă de profit

16.738

Angajați

11,000

EBITDA

-52M

337M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+19.86% upside

Dividende

By Acuity

Următoarele câștiguri

29 iul. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

3B

27B

Deschiderea anterioară

68.54

Închiderea anterioară

69.73

Sentimentul știrilor

By Acuity

18%

82%

35 / 342 Clasament în Healthcare

DexCom Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Despre DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat